Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
EP: 1.How Uveal Melanoma Differs from Cutaneous Melanoma
EP: 2.Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient
EP: 3.Historic and Current Treatment Options for mUM
EP: 4.Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM
Now Viewing
EP: 5.Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
EP: 6.An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources
EP: 7.Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy
EP: 8.Advice for Patients Living with Metastatic Uveal Melanoma
Related Videos
Related Content
